Drugs / Pixatimod
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02042781 | Jan 2014 → Jun 2016 | cancer | Zucero Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01252095 | Jan → Oct 2011 | neoplasm | Zucero Pty Ltd | Terminated | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05061017 | Dec 2021 → Feb 2024 | colorectal carcinoma, non-small cell lung carcinoma | Diwakar Davar | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pixatimod | “Pixatimod (PG545) is a novel clinical-stage immunomodulatory agent capable of inhibiting the infiltration of tumor-associated macrophages (TAMs)” PMID 29898788 ↗ Jun 2018 |
| Known as | Pg-545 free acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL2078841 ↗ |
| Known as | PG545 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01252095 ↗ |
| Action | Activate | “Pixatimod is an investigational drug that activates the toll-like receptor 9 (TLR9) pathway.” NCT05061017 ↗ |
| Route | Subcutaneous | “Subcutaneous Injection” NCT01252095 ↗ |
| Target | TLR9 | “Pixatimod is an investigational drug that activates the toll-like receptor 9 (TLR9) pathway.” NCT05061017 ↗ |